Anamnesis 75 year old man, without known drug allergies, ex-smoker for 7 years with a total cumulative dose of 50 pack-years, without other toxic habits.
Medical-surgical history » Subclinical hypothyroidism in the context of surgery and radiotherapy in the cervical area, diagnosed in September 2015.
Search strategy: Search strategy.
Posterior vitreous layer of the left eye diagnosed in 2011 as a result of routine control in mental health, underwent laser treatment in 2011.
A social-functional situation, when he was retired, worked as a builder.
She lives with her wife on the floor without arquitectonic barriers.
Barthel 100 points.
Usual medication Lorazepam 0.5 mg in the evening if needed.
Acetaminophen 1 g every 8 hours if you need pain.
Location: 100 mcg every 24 hours from Monday to Friday 125 mcg;
▁Oncological history diagnosed in November 2011 of high grade squamous cell carcinoma in the left vocal cord due to dysphonia of two months of evolution.
Left vocal cord injury (LVC) with involvement of the anterior commissure and extension to the right vocal cord (DVC) was observed, performing laser cordectomy in an external center.
At that time, cT1bN0M0; pT1N0M0.
» First recurrence, local: - In December 2012 he came to the Emergency Department due to dysphonia, showing IVC paralysis and hypomobility of CVD, performing urgent anastomosis.
On presentation in a committee, it was decided to perform intraoperative microlaryngoscopy with perioperative biopsies, being positive for malignancy, so a total laryngectomy was performed on January 11, 2013.
Pathological Anatomy Report highlights the presence of moderately differentiated squamous carcinoma, preexisting 3.5 cm in the maximum axis, with invasion of the pyriform sinus, glotis and sub-latraglottic extension, as well as the cartilaginous
Perineural and vascular margins are present and tracheal margin is free.
With this, she presents a local recurrence and stayed as rpT4NxM0.
- Treatment: she underwent adjuvant radiotherapy from 21/2/2013 to 6/5/2013, with a total dose of 66 gray (Gy) in surgical bed and 50 Gy to lymph node chains, by intensity modulated radiation therapy (IMRT).
» Second lymph node recurrence: - In January 2014, a poorly defined lesion was observed in the control neck CT scan at level IV right ganglion, performing a FNAC in this lesion that was positive for malignant cellularity.
In March 2014, right radical cervical lymph node dissection was performed in 4 of the 6 nodes, extracutaneous invasion in 2 nodes and perineural invasion.
- Treatment: performs chemoradiotherapy concomitantly with cisplatin (CDDP) 40/m2 weekly and a total dose of 66 Gy by cisplatin, from 12/5/2014 to 23/6/2014, well-known as IMRT.
» Third recurrence, not resectable.
- In March▁2015, due to the suppuration of the peritracheostomy area, there was an ulcerated area in that location, with computed tomography (CT) showing the presence of peritracheostomy lobule peritracheostomy, contractiler left thyroid gland and contracture,
The extension study with positron emission tomography (PET-CT) is negative.
A biopsy was performed showing the presence of poorly differentiated carcinoma.
- Treatment: from April 7, 2015 to July 13,▁2015, 5 cycles of 5-fluorouracil (5-FU)-cetuximab were performed, with stable disease as the best response after 3 cycles.
Current disease The patient goes to the outpatient clinics of Ontario Medical Center in July 2015; the presence of relapse in the paratracheostomy area was diagnosed with control CT.
The patient is asymptomatic, denies pain or suppuration peritracheostomy.
In order to perform the prescription for the HAWK study (NCT02207530 durvalumab in PD-L1 positive patients), locoregional recurrence biopsy was performed.
Personal hygiene.
Weight 72 kg.
» Oral cavity: no pathological findings.
» Neck: lesion in peritracheostomy area, without signs of local infection.
No neck lymphadenopathy or supraclavicular area was observed.
» Pulmonary physical condition: conserved vesicular murmur, without overlapping sounds.
» Cardiovascular fixation: cardiac rhythmic tones, without added murmurs.
» Abdomen: blando, no signs of peritoneal irritation.
neurological impairment: no signs of acute neurological focality.
▁Complementary tests Locoregional recurrence biopsy (24/7/2015): by immunohistochemistry with qualitative test VENTANA PD-L1 (SP263, a monoclonal antibody of mouse against PD-L1 uptake) was demonstrated.
Pathogenicity was determined by immunohistochemistry.
Diagnosis The patient is diagnosed with unresectable locoregional recurrence of his disease, negative PD-L1.
Treatment Given the negativity for PD-L1, the patient is proposed to enter the D4193 (CONDOR) clinical trial.
On August 27, 2015 the patient signed the informed consent to participate in the study and was randomized to receive durvalumab 20 mg/kg + tremelimumab 1 mg/kg every 4 weeks for 4 cycles.
He finished treatment in September 2016.
The patients condition progressed rapidly in the form of a local symptomatic control, achieving a partial radiological response (according to the diagnostic criteria) in March 2016.
The patient remained in partial response until the end of treatment in September 2016.
After that, he has maintained the partial response until the last control in January 2018, where the disease progressed in the form of mediastinal lymphadenopathy, then restarting treatment within the same clinical trial.
No immune-mediated toxicity was observed at any time.
